Aumake Wins $10M Exclusive Distribution Deal for EZZ Life Science Products

Aumake Ltd has been appointed exclusive global distributor for a range of co-developed EZZ Life Science products under a four-year agreement announced on 17 February 2026. The Aumake EZZ Distribution Agreement includes minimum purchase commitments of $10 million over the initial term, with $2.5 million in minimum annual purchases. EZZ Life Science (ASX: EZZ) retains full intellectual property ownership and brand control whilst outsourcing global distribution execution to Aumake (ASX: AUK).

EZZ Life Science secures $10 million global distribution deal with Aumake

The partnership between the two ASX-listed companies centres on exclusive co-developed EZZ-branded products, with Aumake responsible for managing sales, distribution and channel execution across all territories. The agreement commences in February 2026 and includes automatic renewal periods subject to performance thresholds.

For EZZ shareholders, the structure provides a predictable revenue floor of $2.5 million annually whilst maintaining disciplined capital allocation. Rather than building expensive international distribution infrastructure, EZZ leverages Aumake’s established platform to access global channels without substantial upfront capital expenditure.

The agreement includes termination provisions if minimum purchase thresholds are not met. Failure to achieve either the aggregate $10 million commitment or the annual $2.5 million minimum triggers automatic termination of worldwide exclusive rights, protecting EZZ from underperforming partnerships.

Agreement structure and performance thresholds

The exclusivity arrangement is conditional on Aumake meeting contractual minimums, with EZZ retaining full control over product specifications, brand guidelines and operational standards. Aumake will execute distribution activities in accordance with EZZ’s requirements whilst EZZ maintains oversight of product integrity, branding and compliance.

Performance-linked exclusivity ensures Aumake must deliver measurable results to maintain distribution rights. The structure builds in downside protection, with EZZ able to terminate exclusivity if the distributor fails to meet either aggregate or annual thresholds. This accountability mechanism is critical for investors assessing partnership execution risk.

What is a distribution agreement and why does it matter for investors?

A distribution agreement is a commercial arrangement where one company (the distributor) is appointed to sell and deliver another company’s products to end customers. In consumer health and life sciences, exclusive distribution partnerships allow product developers to access established sales networks without building their own international infrastructure.

The alternative would require EZZ to establish its own sales teams, logistics networks, warehousing facilities and channel relationships in multiple territories. This demands substantial capital investment and operational management, with extended timeframes before generating revenue.

By appointing an exclusive distributor, EZZ immediately gains access to Aumake’s existing platform whilst keeping capital on the balance sheet. The trade-off involves sharing margins with the distributor and relying on partner execution, but the Aumake EZZ Distribution Agreement mitigates execution risk through binding minimum purchase commitments.

Key benefits of exclusive distribution partnerships include:

1. Access to established sales channels and logistics infrastructure
2. Reduced operational burden and capital requirements for the brand owner
3. Performance accountability through minimum purchase commitments

For EZZ shareholders, this model allows global scaling without diluting capital reserves or diverting management attention from product development and brand building.

Why Aumake as the distribution partner?

Aumake Limited specialises in delivering Australian and New Zealand brands to Asian markets, with established brand acceleration and sales capabilities. As an ASX-listed company with platform experience in cross-border commerce, Aumake brings channel relationships and distribution infrastructure that complement EZZ’s product development strengths.

The strategic fit reflects EZZ’s existing presence across Australia, New Zealand and China, with Aumake positioned to accelerate penetration in these markets whilst extending reach to other territories. The partnership leverages complementary capabilities rather than duplicating functions, with EZZ focused on product development and brand integrity whilst Aumake executes distribution and channel management.

For investors, the appointment of an ASX-listed distributor provides transparency, with Aumake subject to continuous disclosure obligations. This allows shareholders to monitor partner performance and assess whether distribution execution aligns with contractual commitments.

Management commentary on the strategic rationale

Chief Executive Officer Mark Qin framed the appointment as an expansion of EZZ’s international distribution capability, emphasising the focus on maintaining brand standards whilst scaling selected products across global channels.

Mark Qin, Chief Executive Officer

“The appointment of Aumake as an exclusive global distributor represents an important step in expanding EZZ’s international distribution capability. Aumake’s established infrastructure and platform experience provide an opportunity to scale selected EZZ products across global channels, while maintaining our focus on brand integrity and product quality.”

The commentary highlights management’s prioritisation of controlled expansion. Rather than pursuing rapid distribution at any cost, the partnership structure maintains EZZ’s oversight of product quality and brand positioning whilst outsourcing operational execution.

What this means for EZZ’s growth strategy

The agreement aligns with EZZ’s omnichannel distribution model across Australia, New Zealand, China and worldwide. Products covered under the Aumake EZZ Distribution Agreement are exclusive co-developed EZZ-branded items, creating differentiation in market rather than distributing existing catalogue products.

Co-developed exclusives generate mutual alignment between EZZ and Aumake. The distributor has incentive to prioritise these products given exclusivity rights, whilst EZZ retains long-term intellectual property value and control over product specifications. This structure prevents channel conflicts and ensures focused distribution execution.

Key strategic elements include:

• Global exclusivity across all sales channels eliminates territorial fragmentation
• Co-developed products create shared commercial interest in success
• EZZ retains IP ownership and brand control, protecting long-term asset value
• Automatic renewal provisions subject to performance incentivise consistent execution

The capital-light approach allows EZZ to maintain financial flexibility whilst expanding revenue potential. By avoiding the capital expenditure required to build international distribution infrastructure, the company preserves resources for product development and brand investment.

Looking ahead: key milestones to watch

Following the announcement, investors should monitor near-term execution indicators that demonstrate partnership progress. The first product launches under the agreement will signal operational commencement, followed by channel activation across Aumake’s distribution network.

Revenue recognition from Aumake purchases will appear in EZZ’s financial reporting, with the annual $2.5 million minimum providing a clear performance benchmark. Investors can assess partnership success against this contractual threshold through quarterly and annual results.

Milestones to track include:

1. First product launches under the Aumake EZZ Distribution Agreement
2. H2 FY26 and FY27 revenue recognition from Aumake purchases
3. Aumake’s progress toward annual $2.5 million minimum commitment
4. Potential renewal or expansion announcements beyond the initial four-year term

The $2.5 million annual floor creates accountability for both parties. If Aumake fails to meet minimums, EZZ retains the right to terminate exclusivity and seek alternative distribution partners. Conversely, consistent performance above minimums may support contract expansion or additional product categories being added to the distribution agreement.

For investors, the predictable revenue floor provides visibility over baseline income from the partnership, with upside potential if Aumake exceeds minimum commitments through successful channel execution and market penetration.

Ready to Learn More About EZZ’s $10 Million Distribution Partnership?

EZZ Life Science has secured a four-year exclusive global distribution agreement with Aumake, providing a predictable $2.5 million annual revenue floor whilst maintaining full IP ownership and brand control. The capital-light partnership allows EZZ to scale internationally without building expensive distribution infrastructure.

To explore how this agreement fits into EZZ’s broader commercialisation strategy and review the company’s full product pipeline, visit the EZZ Life Science investor centre for detailed announcements, financial reports and strategic updates.